French researchers at Eligo Bioscience and collaborators published results on EB-003, a CRISPR-based antimicrobial approach targeting Shiga toxin-producing E. coli (STEC). The strategy comes amid ongoing limitations in clinical management, as antibiotics are generally not recommended for STEC infections and treatment is often symptomatic. STEC can cause severe disease including hemolytic uremic syndrome, particularly in children, with reported incidence risks in a substantial minority of cases. By using CRISPR targeting, the approach aims to neutralize or reduce pathogenic bacterial burden without relying on conventional antibiotics. The publication is positioned as a potential alternative mechanism class for future development, particularly for situations where antibiotic use is constrained.